复发的急性淋巴细胞白血病复发
Jasmeet Sidhu1,2,3, Manash Pratim Gogoi2, Shekhar Krishnan1,2,4
1Department of Pediatric Hematology and Oncology, Tata Medical Center, Kolkata, 700160, India.
Indian journal of pediatrics
|June 21, 2023
概括
儿童急性淋巴细胞白血病 (ALL) 的结果有所改善,但复发的ALL仍然是一个重大的挑战,稳定生存率. 新的免疫疗法,细胞疗法和精确瘤学策略对于改善复发ALL的结果至关重要.
科学领域:
- 儿科瘤学 儿科瘤学
- 血液学 血液学 血液学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 在全球范围内,儿童急性淋巴细胞白血病 (ALL) 的生存率超过85%.
- 复发ALL的结果仍然很差,约为50%,对儿童癌症死亡率作出了重大贡献.
- 18个月内早期的骨髓复发预示着一个特别糟糕的预后.
研究的目的:
- 突出治疗复发性急性淋巴细胞白血病 (ALL) 的持续挑战.
- 强调需要对复发和药物耐药性机制有更好的生物学理解.
- 讨论在复发性ALL治疗中整合新型治疗选择和精确瘤学策略.
主要方法:
- 审查当前的治疗支柱:化疗,放射治疗和造血干细胞移植 (HSCT).
- 探索新兴的治疗方案,包括免疫疗法和细胞疗法,用于复发ALL.
- 讨论针对个性化治疗策略的综合精确瘤学方法.
主要成果:
- 尽管ALL治疗总体有所改善,但复发病例的结果并没有显著改善.
- 新的策略,如免疫疗法和细胞疗法提供了潜在的改善结果.
- 精密瘤学越来越多地被用于为个别患者量身定制治疗,特别是那些患有耐火性疾病的患者.
结论:
- 对ALL复发和药物耐药性进行增强的生物学洞察力至关重要.
- 创新的治疗策略和全球合作对于改善复发ALL的存活率至关重要.
- 了解新型疗法和精准医学的最佳应用对于推进复发性ALL的护理至关重要.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Primary Lymphoid Organs
1.7K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
1.7K


